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Abstract
Background: The production of inflammatory cytokines resulting from amyloid β (Aβ) is associated with the initiation
of Alzheimer’s disease (AD). Atorvastatin (ATV) has been reported to improve AD, however, it is unclear how the anti-
inflammatory mechanism is linked with its protection against the impairment of spatial cognitive function in AD. The
present study was designed to explore what mechanism was possibly involved in the anti-inflammatory pathway in
regard to the ATV treatment of AD.
Methods: We used an AD model induced by the administration of Aβ25–35 in male C57BL/6 mice and an in vitro culture
system to study the protective effects of ATV on the spatial cognitive deficits, hippocampal long-term potentiation (LTP)
impairment and inflammatory reaction.
Results: The intragastric administration of ATV (5 mg/kg) in Aβ25–35-treated mice significantly ameliorated the
spatial cognitive deficits and prevented the LTP impairment in hippocampal CA1. The increased Iba-1 positive
cells and inflammatory components in the hippocampus were reduced after the ATV treatment. The anti-inflammatory
and LTP protection of ATV were abolished using the replenishment of farnesyl pyrophosphate by the administration of
farnesol (FOH). The hippocampal slices culture showed Aβ25–35-induced neurotoxicity in the absence of the presence
of ATV. Treatment with ATV (0.5, 1, 2.5 μmol/L) dose-dependently prevented the cell damage in hippocampus induced
by Aβ25–35.
Conclusion: The administration of ATV ameliorated the cognitive deficits, depressed the inflammatory responses,
improved the LTP impairment, and prevents Aβ25-35-induced neurotoxicity in cultured hippocampal neurons.
These protective functions of ATV involved the pathway of reducing farnesyl pyrophosphate (FPP).
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Background
Alzheimer’s disease (AD) is the most common form of de-
mentia, and is characterized by progressive loss of memory
and cognition [1]. The initiation and progression of AD in-
volve many different factors, such as Aβ42/Aβ40 ratio, ele-
vation of cholesterol levels, oxidative stress, alterations in
cholinergic nervous system and pro-inflammatory cyto-
kines [2].
Amyloid β (Aβ) peptide has been shown to enhance
microglial activation [3], and increase the production of in-
flammatory cytokines interleukin-1β (IL-1β), interleukin-
6(IL-6) and tumor necrosis factor-α (TNF-α) [4–6]. Aβ
25–35 has been shown to have neurotoxic properties and
to affect cognitive processes [7]. The short fragment repre-
sents the core functional domain of the full length Aβ pep-
tide, and is able to self-assemble to form a predominantly
β -sheet structure [8]. Therefore, our study used Aβ-25-35,
instead of full-length Aβ, to establish the animal model of
AD for studying neuro-toxic properties of AD and evalua-
tions of anti-AD drugs [9]. The pro-inflammatory cyto-
kines exacerbate the disease process, cause neuronal death
[10], and disrupt synaptic function and induction of long-
term potentiation (LTP) [11]. The anti-inflammatory
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agents have been reported to protect the Aβ-induced dam-
ages [12].
Atorvastatin (ATV), as a member of statins family, has
been reported to decrease AD risk [11, 12]. Even though
ATV is documented to attenuate the Aβ-induced inflam-
matory production, such as IL-1β, IL-6 and TNF-α, in
the hippocampus [6], it is not fully clear whether the
anti-inflammatory function is potentially linked with its
protective effects on the spatial cognitive function. The
present study, therefore, was designed and used farnesol
(FOH), LY294002 and corticosterone (CORT) to exam-
ine whether the improvement of cognitive impairment
by ATV-treatment involves the pathway of LTP induc-
tion in regard with the anti-inflammatory response fol-
lowing the administration of Aβ25-35 in animal model.
In addition, an in vitro culture system was used to exam-
ine the toxicity of Aβ-peptide and the dose-dependent
protective effects of ATV in cell cultures.
Methods
Animal allocation
The animals were handled according to the guidelines of
the Care and Use of Laboratory Animals (NIH USA), and
the Animals Scientific Procedures Act (UK).
The study was submitted to and approved by the Ethics
Committee of Nanjing Medical University, China (NMU-
103-2014).
Male C57BL/6 mice (Oirental Bio Service Inc., Nanjing),
weighing 20–25 grams, were housed in a controlled room
under a12-h light/dark cycle, and had free access to a
standard pellet chow and tap water throughout the study.
A total of ninety-six animals were randomly divided into
the groups: Aβ (n = 8), Aβ +ATV (n = 8), Aβ +ATV +
Farnesol (FOH) (n = 8), Aβ + ATV + LY294002 (n = 8),
Aβ + Corticosterone (CORT) (n = 8), Aβ + CORT +
ATV (n = 8) and their relevant controls (8 in each). The
study was completed 15 days after the administration
of Aβ25–35 (Fig. 1).
Preparation of AD model
The AD model was prepared according to the previously
reported method [6]. Briefly, Aβ25–35 (Sigma Chemical
Co., St. Louis, MO, USA) was dissolved in a sterile bi-
distilled water at a concentration of 2 mg/ml, and incu-
bated at 37 °C for 4 days. 40 mg/kg of chloral hydrate
was intraperitoneally administrated, and the animals
were placed in a sterotactic device (Kopf Instruments,
Tujunga, CA, USA). A volume of 3 μl of Aβ was injected
into the right lateral ventricle, at the following coordi-
nates at 3 mm posterior, 1 mm lateral and 2.5 mm ven-
tral to bregma, using a stepper-motorized micro-syringe
at a rate of 0.5 μl/min. The mice serving as the control
group were administered with scrambled Aβ25–35 pep-
tide (NeoMPS, Strasbourg, France) dissolved in a sterile
bi-distilled water at the same volume.
Drug administration
ATV
Four hours after the injection of Aβ25–35, the animals
were intragastrically administered with ATV (Lipitor,
Pfizer-Parke Davis, Ireland) mixing with food at a dose
of 5 mg/kg per day. The animals were weighed at inter-
vals, and the dose was accordingly adjusted throughout
the study. The chosen doses of ATV was based on the
previous studies [6].
Farnesol (FOH)
FOH (Sigma, Cat# 277541, St. Louis, MO, USA) was ad-
ministrated by a gavage feeding or perfusion in slices. For
the gavage feeding, FOH was administrated intragastrically
at a dose of 100 mg/kg/day, as described previously [13, 14].
The intragastric administration of FOH started 30 min
Fig. 1 Time chart of experimental procedures. Hidden platform and probe trial test in Morris water maze (MWM) and Y-maze task was performed
on days 5–11 and day 13 after Aβ25–35-injection, respectively. On day 14–15 after Aβ25–35-injection the mice were killed for electrophysiological recording
LTP, histological examination (HE), Western blot (WB) and RT-PCR analysis. ATV, ATV + FOH, ATV + LY294002 (LY) or CORT were consecutively administered
after Aβ25–35-injection. FOH or LY294002 was administered 30 min before ATV-treatment
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before ATV administration. The group serving as controls
received saline only. For the perfusion in slices, following
the previously described method [15], 1.85 μl of FOH was
pipetted into 4 μL of 0.01 % ethanol, and then diluted
into 40 ml of artificial cerebral spinal fluid to reach a
final concentration of 2 μM. The control was infused
with ethanol only.
LY294002
LY294002 (ApeBio, Houston, TX, USA), a potent inhibitor
of phosphoinositide 3-kinases (PI3K), was prepared as the
previously reported method [16]. Briefly, LY294002 was
dissolved in dimethyl sulfoxide (DMSO), and mixed with
saline to reach 1 % as a final concentration. LY294002 was
intra-cerebroventricularly injected 30 min before the injec-
tion of ATV. For daily intra-cerebroventricular injection of
LY294002, a 26-G stainless-steel guide cannula (Plastics
One, Roanoke, VA, USA) was implanted into the right lat-
eral ventricle and anchored to the skull with four stainless-
steel screws and dental cement. The drug was injected
using a stainless-steel needle combining with a stepper-
motorized micro-syringe (Stoelting, Wood Dale, IL, USA)
at a rate of 0.5 mL/min in a volume 3 mL/mouse. The con-
trol group were given the same volume of vehicle.
Corticosterone (CORT)
CORT (Sigma, St. Louis, MO, USA) was dissolved in etha-
nol (50 mg/mL), and diluted in sesame oil (8 mg/mL). Fol-
lowing the previously reported method [15], CORT was
subcutaneously administrated at a dose of 40 mg/kg/day
30 min before the ATV administration. The controls re-
ceived the same amount of ethanol/oil mixture.
Y-maze task
The animals started with Y-maze task on day 13 after the
administration of Aβ25–35. The Y-maze was performed as
described previously [17]. Briefly, both the start arm
(27.5 cm long) and two arms forming the Y (both 27.5 cm
long and diverged at a 60° angle from the stem arm) were
5 cm in diameter. The home cage was connected to the
start arm of the Y-maze. Each mouse was placed at the
end of one arm, and allowed to move freely through the
maze during an 8 min session. The series of arm entries
was recorded visually, and arm entry was considered to be
completed when the hind paws of the mouse were com-
pletely placed in the arm. Alternation was defined as suc-
cessive entries into the three arms on overlapping triplet
sets. The percentage alternation was calculated as the ratio
of actual to possible alternations.
Morris water maze
The animals started with Morris water maze on day 5
after the injection of Aβ25–35. A circular pool with diam-
eter at 120 cm was prepared with the water temperature
at 24 ± 1 °C. Ink powder was used to render the water
opaque. Swim paths were analyzed using a computer sys-
tem with a video camera (Neuroscience, Inc., Tokyo, Japan).
The platform (7 cm in diameter) was submerged 1 cm
below the water surface. Mice were given 90 s in the pool
to search the hidden platform. If no platform was found
within 90 s, the mouse was guided to the platform, and the
trial was terminated. Each mouse started in one of four
quadrants in a random manner, with the head facing the
wall. Four trials were conducted each day, for six consecu-
tive days. The probe trial was then recorded by removing
the platform. The mouse was released from opposite quad-
rant in which the platform was located, and allowed to
swim for 90 s to determine its search patterns. Times spent
in platform quadrant, opposite quadrant, adjacent right and
left quadrants were measured. The percentage of time
spent in each quadrant was determined.
Slice preparation and electrophysiology
Hippocampal slice preparation was performed as previ-
ously reported [18, 19] with modifications. Briefly, the ani-
mals were decapitated under deep anesthesia with ethyl
ether (400 mg/kg, intraperitoneal injection), and the
brains were rapidly removed out. Coronal slices (400 μM)
of dorsal hippocampi were cut on a vibrating microtome
(Dousaka EM Co, Kyoto, Japan) in an ice-cold cutting so-
lution, and then incubated in artificial cerebrospinal fluid
at 30 ± 1 °C for 60 min. After a slice was submerged in a
recording chamber, hydraulic micromanipulators (Narishige,
Tokyo, Japan) mounted on the microscopy were used to
place a stimulating electrode in radiatum layer. Constant
current pulses (0.1 ms, 0.06 Hz) were supplied by a stimu-
lator (Nihon Kohden, Japan). The excitatory post-synaptic
potential (EPSP) slope was recorded from radiatum layer
with a 5 MΩ resistance glass microelectrode, and con-
nected to a neutralized high input-impedance preampli-
fier. Stability of baseline recordings was established by
delivering single pulses (four/min, 0.1 ms pulse width) for
15 min prior to collection of input/output functions. Base-
line synaptic transmission was assessed by averaging the
response to five pulses (from 0.1 to 1.0 mA) delivered at a
rate of 0.06 Hz. Paired-pulse facilitation (PPF) was mea-
sured by using the intensity of the test stimulus with an
inter-pulse interval of 25–100 ms. Pre-train responses
were recorded for 20 min (baseline), high-frequency stim-
uli (100 Hz, 100 pulse) were used to induce LTP.
Histological examination
Mice were anesthetized by intraperitoneal injection of
chloral hydrate (40 mg/kg), and transcardially perfused
with ice-cold phosphate-buffered saline followed by 4 %
para-formaldehyde. The brains were quickly taken out,
immersed in 4 % para-formaldehyde for fixation at 4 °C
overnight, and processed for paraffin embedding. Coronal
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sections (5 μm) of hippocampus were prepared for the
histological examination. The sections were treated with
3 % H2O2 for 10 min, and then incubated in 5 % goat
serum for 30 min. For Iba-1 staining, the sections were in-
cubated with a goat polyclonal anti-Iba-1 antibody (Abcam,
Cambridge, UK), and then incubated in biotin-labeled anti-
goat IgG antibody (Bioworld Technology, Inc., St. Louis
Park, MN, USA) for 2 h at room temperature. The immu-
noreactivity was visualized by the standard avidin-biotin
complex reaction with 3, 3′-diaminobenzidine (Vector La-
boratories, Burlingame, CA, USA). Iba-1 positive cells were
counted using a light microscope (Olympus, Japan). The
density of Iba-1 positive cells was expressed as the mean
number of Iba-1 positive cells per mm2.
Fig. 2 ATV ameliorates spatial cognitive deficits in Aβ25–35-mice. a Hidden-platform test in Morris water maze. Each point represents group mean
latency (sec) to reach the hidden-platform in control mice (control), ATV-treated control mice (control/ATV, n = 8), Aβ25–35-mice (n = 8) and
ATV-treated Aβ25–35-mice (Aβ25–35/ATV, n = 8). **P < 0.01 vs. latency on day 1 (comparisons within each group);
##P < 0.01 vs. control mice;
++P < 0.01 vs. Aβ25–35-mice (two-way ANOVA). b Swim speed (m/s) in Morris water maze. c In probe test, bars present the percentage of time
spent in platform, opposite, right and left adjacent quadrants. *P < 0.05 vs. platform quadrant (comparisons within each group); #P < 0.05 vs.
control mice; +P < 0.05 vs. Aβ25–35-mice (two-way ANOVA). d Bar graph shows group mean of alternation rate (%) in Y maze task. **P < 0.01 vs.
control mice; ##P < 0.01 vs. Aβ25–35-mice (two-way ANOVA)
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Hippocampal cell culture
Hippocampal slice cultures were prepared according to
the previously reported method [20]. Briefly, mice were
decapitated 15 days after Aβ25-35 administration. The
brain was removed, and 400 μm of hippocampal slices
were prepared, and separated in ice-cold HBSS solution
with a pH value of 7.2. On average, six slices from the
middle of hippocampus were obtained and placed in a
12-wells plate. The cells served as control group were
from the animals without administration of Aβ25-35.
The cell cultures were maintained in an incubator for
1 h before performing cell viability.
Atorvastatin (ATV) preparation and cell treatments
The animals without Aβ25-35 administration were decap-
itated. Hippocampal slice cultures were prepared as re-
ported previously [20]. To examine the dose-dependent
protective effects of ATV, different doses at 0.5, 1 and
2.5 μmol/L in the culture medium were used. The cells
cultures were maintained in an incubator with a 5 % CO2
mixed with 95 % O2 at 37 °C for 14 days, and the medium
were replaced at every exchange of culture medium. The
cells served as control group were treated with DMSO
only in culture medium. The doses of ATV was chosen as
described previously [21], which was confirmed to gener-
ate the dose-dependently inhibited effects.
Quantification of cellular death
Cell death was assessed by using fluorescent exclusion dye
propidium iodide (PI) uptake. PI is a polar compound that
penetrates damaged cells only, and binds to nuclear DNA
to generate a bright red fluorescence. The appearance of
PI uptake is cellular membrane injury [22]. After 14 days
of ATV exposure, 7 μm/ml of PI was added to the culture
medium, and incubated for 40 min at 37 °C. Cultures were
observed with an inverted microscope (Leica Microsys-
tems Inc., Wetzlar, Germany) using a standard rhodamine
filter set. The images were taken with an Olympus camera,
and analyzed using Scion Image Software (http://scion-
image.updatestar.com).
Western blot analysis
Mice were decapitated under a deep anesthesia with
chloral hydrate. Hippocampus was quickly taken out,
Fig. 3 ATV rescues impairment of LTP induction in Aβ25–35-mice.
a Input–output function at Schaffer collateral-CA1 synapses. EPSP
slopes plotted against stimulus intensity (0.1–0.9 mA) in control mice
(n = 8), ATV-treated control mice (control/ATV, n = 8), Aβ25–35-mice
(n = 8) and ATV-treated Aβ25–35-mice (Aβ25–35/ATV, n = 8). b Induction
of LTP by HFS (100 Hz, 100 pulses). Each point represents group mean
EPSP slopes expressed as percentage of baseline. A solid arrow
indicates when HFS was given. c Influence of ATV on Aβ25–35-impaired
LTP induction
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and homogenized in a lysis buffer (Roche, Mannheim,
Germany). Protein concentration was determined accord-
ing to the instruction of the Protein Assay Kit (Pierce Bio-
technology, Inc., Rockford, IL, USA). The membranes
were incubated and developed by following the instruction
of the ECL detection Kit (Millipore, Massachusetts, USA).
Western blot bands were scanned and analyzed with the
image analysis software package (NIH Image, Bethesda,
MD, USA).
Reverse transcription-polymerase chain reaction (RT-PCR)
Hippocampus was micro-dissected, and stored at −80 °C
until assayed. RNA was isolated using Trizol reagent (Invi-
trogen, Camarillo, CA, USA), and reverse-transcribed into
cDNA according to the instruction of Prime Script RT re-
agent kit (Takara Bio. Mountain View, CA., USA) for
quantitative PCR in the presence of a fluorescent dye
(Takara Bio. Mountain View, CA., USA). Relative ex-
pression of genes was determined using the reported
method [23]. The levels of IL-1β and TNF-α mRNA
were normalized by controls. The primers of IL-1β are
5′-CCATGGCACATTCTGTTCAAA-3′ and 5′-GCCC
ATCAGAGGCAAGGA-3′; the primers of TNF-α are
5′-ACGGCATGGATCTCAAAGAC-3′ and 5′-CGGAC
TCCGCAAAGTCTAAG-3′; the primers of GAPDH
are 5′-ACCACAGTCCATGCCATCAC-3′ and 5′-TCC
ACCACCACCCTGTTGCTGTA-3′.
Statistics analysis
The group data were expressed as the means ± standard
error (SE). All statistical analyses were performed using
SPSS software, version 16.0 (SPSS Inc., Chicago, IL, USA).
Differences among means were analyzed using regressions
analysis of variance. Differences at P < 0.05 were consid-
ered statistically significant.
Results
ATV improved spatial cognitive function impaired by
Aβ25–35
Spatial cognitive performance was examined on day 5–11
after Aβ25–35-injection. The results from Morris water
maze showed that the Aβ25–35-treated animals needed a
longer time to find the hidden platform than those non-
injection of Aβ25–35 (P < 0.01). The spatial cognitive im-
pairment was significantly improved by the administration
of ATV (P < 0.01). Even though no significant difference
was observed in the swim speed, the swimming time spent
in the platform quadrant was less in the Aβ-treated ani-
mals (P < 0.05). The decrease in the swimming time was
improved after the administration of ATV. The results
from the Y-maze test demonstrated that the administra-
tion of Aβ25–35 significantly decreased the spontaneous al-
ternation behavior (P < 0.01), while the decrease was
greatly reversed by the administration of ATV (P < 0.01).
Those results suggested that ATV had anti-amnesic ef-
fects (Fig. 2a-d).
ATV protected long-term potentiation (LTP) against
impairment resulting from Aβ25–35
The slopes of excitatory postsynaptic potential (EPSP)
using 0.1–0.9 mA stimuli did not difference in slices be-
tween the Aβ25–35-treated and control groups. A high-
frequency stimulation (100 pulses at 100 Hz, 0.5 s in
duration, 20 s interval) evoked an increase in EPSP slopes
for over 60 min in the control group, but this increase was
not seen in the Aβ-treated animals. The impairment of
LTP caused by Aβ25–35 were fully reversed by the adminis-
tration of ATV (Fig. 3a-c).
ATV inhibited inflammatory responses resulting from the
administration of Aβ25–35
The inflammatory production of IL-1β and TNF-α in the
hippocampus were examined using the immunohisto-
chemistry, Western blot and RT-PCR methods. The Aβ25–
35 treatment caused a number of ionized calcium-binding
adaptor molecule 1 (Iba-1) positive cells in pyramidal cell
and radiatum layers, while the administration of ATV sig-
nificantly prevented the responses (P < 0.01). Furthermore,
the administration of Aβ25–35 resulted in elevations of
IL-1β mRNA (P < 0.01), IL-1β protein (P < 0.05), TNF-α
mRNA (P < 0.01) and TNF-α protein (P < 0.01), while
the administration of ATV greatly attenuated those in-
creases (Fig. 4a-f ).
FOH blocked the anti-amnesic and anti-inflammatory
effects of ATV
To test whether the anti-amnesic and anti-inflammatory
effects of ATV were due to the reduction of farnesyl-
pyrophosphate (FPP), we used FOH converting to FPP via
endogenous salvage mechanisms. The results from the hid-
den platform task, probe test, and LTP induction showed
that the administration of FOH blocked the protective
(See figure on previous page.)
Fig. 4 ATV inhibits the Aβ25–35-induced inflammatory responses in hippocampus. a Images of Iba-1 immunostaining in hippocampal CA1 of control
mice (n = 8), ATV-treated control mice (control/ATV, n = 8), Aβ25–35-mice (n = 8) and ATV-treated Aβ25–35-mice (Aβ25–35/ATV, n = 8). Black arrows indicate
Iba-1 positive cells. Scale bar = 50 μm. Or: oriens layer; Pm: pyramidal layer; Ra: radiatum layer. b Bar graphs show mean number of Iba-1 positive cells.
**P < 0.01 vs. control mice; ##P < 0.01 vs. Aβ25–35-mice (one-way ANOVA). c & d Bars present mean levels of IL-1β mRNA and IL-1β protein. **P < 0.01
and *P < 0.05 vs. control mice; ##P < 0.01 and #P < 0.05 vs. Aβ25–35-mice. e & f Bar graph show mean levels of TNF-α mRNA and TNF-α protein.
**P < 0.01 vs. control mice; ##P < 0.01 vs. Aβ25–35-mice
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effects of ATV on the Aβ25–35-impaired cognitive perform-
ance. In addition, the administration of FOH remarkably
attenuated the inhibitory effects of ATV on the Aβ25–35-in-
creased number of Iba1-positive cells (P < 0.01), the levels
of IL-1β mRNA (P < 0.01) and TNF-α mRNA (P < 0.01,
Fig. 5a-f).
LY294002 inhibited the anti-amnesic and anti-inflammatory
effects of ATV
LY294002 is an inhibitor of phosphoinositide 3-kinases
(PI3K). ATV-enhanced LTP induction depends upon the
PI3K/Akt activation [24]. Our results revealed that the ad-
ministration of Aβ25–35 significantly decreased the level of
Akt phosphorylation (phosphor-Akt) in the hippocampus
(P < 0.05), the decrease was significantly recovered by the
administration of ATV (P < 0.01). Moreover, the adminis-
tration of LY294002 in the ATV-treated Aβ25–35-animals
did not affect the spatial cognitive in hidden platform task,
probe test, and LTP induction. Similarly, after the admin-
istration of LY294002, the effects of ATV on the micro-
glial activation, and expressions of IL-1β and TNF-α in
the Aβ25–35-treated animals were inhibited (Fig. 6a-g).
Corticosterone (CORT) inhibited the inflammatory reaction
and recovered LTP impairments causing from Aβ25–35
To determine whether, through suppressing the Aβ25–35-
induced inflammation, ATV protected the LTP induc-
tion and spatial memory. Our results showed that CORT
decreased the number of Iba1-positive cells (P < 0.01),
levels of IL-1β mRNA (P < 0.01) and TNF-α mRNA (P <
0.01). After the administration of CORT in the Aβ25–35-
treated animals, the LTP induction was significantly re-
covered. These suggested that ATV protected the LTP
induction and spatial memory was through the suppres-
sion of the Aβ25–35-induced inflammation (Fig. 7a-d).
ATV protected cell death against Aβ25-35 induced damage
As expected, the cellular cultures from the animals treated
with Aβ25-35 demonstrated a significant increase in fluor-
escence in hippocampal slices (P < 0.01), suggesting an in-
crease in the cellular damage or death. These were
significantly reduced by the treatment of 1 (P < 0.05) or
2.5 μmol/L (P < 0.01) of ATV, showing a dose-dependent
protective effects on Aβ-induced cellular damage. Quanti-
fication of PI fluorescence showed that Aβ25-35 caused
an increase in cellular damage (41 %) in the hippocampus,
comparing with controls cultures (4 %). The treatment
with 0.5 μmol/L of ATV did not protect from Aβ25-35
toxicity, however, when cells were treated with 1 and
2.5 μmol/L of ATV, the cell death was decreased to
around 5 (1 μmol/L) and 15 % (2.5 μmol/L), respectively,
suggesting a dose-dependent protection from the Aβ25–35-
induced neurotoxicity (Fig. 8). The fluorescence reduction
seen in the control group represents a minimal damage
due to the slicing of hippocampus tissue.
Discussion and conclusions
The neuroprotective mechanisms of statins therapy are a
discussion topic in the medical literature. Studies suggest
that the treatment with anti-inflammatory and cholesterol-
lowering agents decreases the risk of developing AD. The
most recent study also showed that the inflammatory fac-
tors were linked with the development of AD [6], but the
study did not address what the exact mechanisms were in-
volved. Our present study further confirmed that the ad-
ministration of ATV greatly improved the spatial cognitive
deficits caused by the administration of Aβ25–35, and dem-
onstrated that the cognitive deficits resulting from Aβ25–35
involved inflammatory reaction.
Aβ has been shown to induce the production of pro-
inflammatory cytokines IL-1β, TNF-α and IL-6 from
microglia [5, 14, 25–27], and increase the activation of
microglia, leading to the over-expression of IL-1β and
TNF-α in hippocampus [28, 29]. The increases in these in-
flammatory components seem to link with the progression
of AD [30]. Activated microglia release a diverse array of
pro-inflammatory molecules that exacerbate the disease
process and cause neuronal death [31]. The study by
Boimel et al. [32] showed an anti-inflammatory or anti-
microglial effect in ATV treated mice. The results from
our study were consistent with those previously reported
findings. In addition, a large number of Iba-1 positive cells
was observed after the administration of Aβ25–35. Iba1 is a
calcium-binding protein, and is specifically expressed in
microglia in the brain. The administration of Aβ25–35 not
only increased the number of Iba-1 positive cells, but also
elevated the levels of IL-1β mRNA and IL-1β protein.
However, the administration of ATV significantly attenu-
ated the levels of those inflammatory components and the
number of Iba-1 positive cells. These findings suggest that
the pro-inflammatory responses attribute to the develop-
ment of AD.
(See figure on previous page.)
Fig. 5 Anti-dementia, anti-inflammatory and LTP protection of ATV in Aβ25–35-mice are abolished by replenishment of FPP. a Each point represents
group mean latency to reach hidden-platform in Morris water maze. **P < 0.01 vs. Aβ25–35/ATV. b In probe test, bars show the percentage of time
spent in platform quadrant in Control, Control/ FOH, Aβ25–35/ATV and Aβ25–35/ATV/FOH mice (8 in each group). *P < 0.05 vs. Aβ25–35/ATV. c Induction
of LTP in FOH-treated control mice (n = 8) and Aβ25–35/ATV mice (n = 8). d Bar graph shows mean number of Iba-1 positive cells in control mice (n = 8)
and Aβ25–35/ATV mice treated with FOH (n = 8). **P < 0.01 vs. Aβ25–35/ATV. e & f Bar graphs show mean levels of IL-1β and TNF-α mRNA. **P < 0.01
vs. Aβ25–35/ATV
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Isoprenoids, including farnesylpyrophosphate (FPP),
serve as lipid attachments for all members of the small
GTPase superfamilies [33]. Statins have been estab-
lished to selectively reduce FPP, decreasing the mem-
brane localization of Ras, Rho and Rab proteins. The
inhibition of Rho-family function with Clostridium dif-
ficile Toxin A can reduce the inflammatory response
[13]. The GTPases as molecular switches or timers can
regulate critical cell-signaling pathways including those
involved in inflammation response [34]. Our results
showed that the ATV-increased Akt phosphorylation in
Aβ25–35-treated animals seemed not associate with the
anti-inflammatory effects, as the administration of Aβ25–35
decreased the level of phosphor-Akt, while ATV signifi-
cantly recovered the alteration of phosphor-Akt level.
Therefore, the Aβ25–35-induced inflammatory response
inhibited by ATV is through the pathway of reducing FPP,
and the anti-inflammatory effects can be blocked by the
replenishment of FPP. However, further studies are
needed to identify how the ATV anti-inflammatory mech-
anisms are involved in the pathway of reducing FPP.
In addition to increase the pro-inflammatory cytokines
associated with the deficits in LTP induction and spatial
cognition after administration of Aβ, our finding demon-
strated that the spatial memory deficits were improved by
the administration of ATV. The improvements were obvi-
ously through the anti-inflammatory pathway, as addressed
early in the text, suggesting that the pro-inflammatory cy-
tokines were increased through postsynaptic mechanisms,
which impairs the LTP induction leading to spatial cogni-
tive deficits. These findings also suggested that a modula-
tion of hippocampal LTP was one of the underlying
cellular and molecular mechanisms by which ATV treat-
ment enhanced learning and memory [32].
(See figure on previous page.)
Fig. 6 PI3K inhibitor had no effects on the anti-dementia, anti-inflammatory and LTP protection of ATV. a Western blot of phosphor-Akt in hippocampus
in control and Aβ25–35 mice treated with ATV or FOH. *P< 0.05 vs. control mice; ##P< 0.01 vs. Aβ25–35-mice; $P< 0.05 vs. control/ATV; ++P< 0.01 vs. Aβ25–35/
ATV (two-way ANOVA). b-d Effects of PI3K inhibitor LY294002 (LY) on the anti-dementia, anti-inflammatory and LTP protection of ATV in Aβ25–35-mice
(n= 8). e-g The administration of LY294002, the effects of ATV on the microglial activation, and expressions of IL-1β and TNF-α in the Aβ25-35-treated
animals were inhibited
Fig. 7 CORT inhibits anti-inflammatory and protects LTP protection in Aβ25–35-mice. a Bar graph shows mean number of Iba-1 positive cells in
control mice (n = 8) and Aβ25–35 mice treated with CORT (n = 8). **P < 0.01 vs. control mice; ##P < 0.01 vs. Aβ25–35 (two-way ANOVA). b & c Bar
graphs show mean levels of IL-1β and TNF-α mRNA. **P < 0.01 vs. control mice; ##P < 0.01 vs. Aβ25–35 (two-way ANOVA). d Induction of LTP in control
mice (n = 8) and Aβ25–35 mice treated with CORT (n = 8)
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The mevalonate pathway produces a number of inter-
mediate compounds including FPP associated with the
control of several cell functions through protein prenyla-
tion [35]. In this experimental model as a consequence
of an inflammatory stimuli produced by Aβ injection, a
consumption of mevalonate isoprenoids occurs. In nor-
mal conditions, the isoprenoids are continuously re-
placed through the mevalonate pathway, allowing a good
feedback control of inflammation and a sufficient avail-
ability of intermediates for the synthesis of cholesterol.
However, in the presence of mevalonate pathway defi-
ciencies, the supply of anti-inflammatory isoprenoids is
inadequate, leading to an inflammatory reaction [36]. To
examine if the anti-inflammatory effects of ATV are as-
sociated with a reduction of isoprenoid intermediates,
we employed FOH in the Aβ25–35-treated animals. The
administration of the exogenous isoprenoids FOH, that
have been already shown to reduce inflammatory param-
eters in an animal model [36]. The results of the present
study are in conformity with the reported findings. Our re-
sults showed that the inhibitory effects of ATV on the
Aβ25–35-increased number of Iba1-positive cells and pro-
inflammatory cytokines were attenuated, and the protective
effects of ATV on the Aβ25–35-impaired cognitive perform-
ance were blocked by FOH, suggesting that FOH exerted
as a modulator of LTP induction in area CA1.
The steroid hormone corticosterone (CORT) is re-
leased from the adrenal glands. In the brain, there are
the cellular and molecular targets for the action of
CORT. The regulation of LPT by CORT in the hippo-
campus has been reported in the previous studies [37].
In order to determine whether ATV protected the LTP
induction and spatial memory was through suppressing
the Aβ25–35-induced inflammation, our study used CORT
in the Aβ25–35-treated animals, and our results showed
that CORT had anti-inflammatory effects associated with
a recovery of LTP induction. These confirmed that pro-
tective effects of ATV on the LTP induction and spatial
Fig. 8 ATV attenuates cell damage after the pre-treatment of Aβ25–35 in hippocampal slices cultures. a Representative photomicrographs of PI uptake
in hippocampal slices after the pretreatment with Aβ25–35 and exposure to ATV. b Quantification of PI uptake in response to Aβ25–35 and ATV. Values
are expressed as percentage of cell death in hippocampus. †Compare with Control (P < 0.01), * compare with Aβ (P < 0.05), and ** compare with Aβ
(P < 0.01). No significant difference was seen between Aβ and ATV-0.5 μmol groups
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memory were through suppression of the Aβ25–35-induced
inflammation.
ATV-enhanced LTP depends upon PI3K/Akt activa-
tion [26]. The level of phosphor-Akt in hippocampus of
mice was decreased by the administration of Aβ25–35,
which was recovered by the ATV-treatment. The ATV-
increased phosphor-Akt was blocked by FOH. However,
the administration of LY294002 did not affect the spatial
cognitive, probe test and LTP induction. The inhibitory
effects of ATV on the microglial activation and the ex-
pression of IL-1β and TNF-α in Aβ25–35-mice were in-
sensitive to the administration of LY294002. Our present
data, therefore, proposed that the protections of ATV is
through a suppression of the pro-inflammatory cyto-
kines resulting from Aβ25–35.
On the other hand, the pro-inflammatory cytokines
may link with neuronal dysfunction and cell death in-
duced byAβ25–35 peptide. In this study, we observed a
significantly increased cell damage or death when cells
were pretreated with Aβ25–35. To examine whether
ATV is protective for the cell damage or death, we used
ATV administrated in vitro at different dosages. The
findings demonstrated that the cell damage were greatly
prevented by the ATV treatment with dose-dependently
inhibited effect. In addition, the results from our in vitro
study showed that the paradigm of cellular damage
caused by Aβ25–35 and the protection of ATV treat-
ment were the same with those observed in animal
model. A recent study by Piermartiri et al. [29] has also
indicated that ATV prevents hippocampal cell death and
neuro-inflammation following Aβ administration, and
concluded that the mechanisms of those actions involve
different pathways.
The overall results of our work suggest that Aβ25–35
results in spatial cognitive deficits associated with pro-
inflammatory responses and LTP impairment, and that
ATV treatment protects these impairments against the
anti-inflammatory effects through a reduction of the
FPP production. However, these improvements may also
link with other changes in the circulation, vascular per-
meability and cholesterol-lowering following the ad-
ministration of ATV. Therefore, the further studies are
extremely needed.
Limitation of the study
A cell culture experiment would help to clarify if ATV
treatment reduces the secretion of pro-inflammatory cyto-
kines. However, the results from our study showed that
the paradigms of cellular death caused by Aβ25–35 and
ATV protection observed in vitro culture were similar
with those in animal model. In addition, the inflammatory
cytokines associated with the ATV neuro-protection fol-
lowing Aβ administration has been evidenced in the re-
cent study [29].
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